ContractAgreement • November 7th, 2019 • Syndax Pharmaceuticals Inc • Pharmaceutical preparations • New York
[*] = Certain confidential information contained in this document, marked by brackets, is omitted because it is not material and would be competitively harmful if publicly disclosed.
AMENDMENT NO. 11 TO CLINICAL TRIAL AGREEMENT BETWEEN ECOG-ACRIN CANCER RESEARCH GROUP AND SYNDAX PHARMACEUTICALS, INC.Clinical Trial Agreement • November 7th, 2019 • Syndax Pharmaceuticals Inc • Pharmaceutical preparations
This Amendment No. 11 to Clinical Trial Agreement (the “Amendment” or “Amendment 11”) is entered into as of July 1, 2019 (the “Effective Date”), by and between ECOG-ACRIN Cancer Research Group, on behalf of itself and its member hospitals, institutions and physicians (the “Group,” “ECOG” or “ECOG-ACRIN”), and Syndax Pharmaceuticals, Inc. (“Company” or “Syndax”).
